Medilink Therapeutics Valuation, Funding & Investors

Peptilogics is a Salt Lake City-headquartered clinical-stage biotech developing peptide therapeutics via its IPC platform. This computational system explores novel chemical spaces to design scalable, biologically active peptides. Lead candidate PLG0206 targets prosthetic joint infections, holding FDA Orphan Drug and QIDP designations. The firm advances additional programs in anti-infectives and partnered oncology indications.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.

Biocytogen is a biotechnology company offering end-to-end antibody discovery platforms using gene-edited RenMab mice and B-cell screening. Its services span humanized animal model creation, hybridoma sequencing, and bispecific antibody engineering for oncology and immunology targets. Headquartered in Beijing with US facilities in Wakefield, Massachusetts, Biocytogen partners with over 100 global pharmas including Takeda and Novartis, delivering candidates like fully human antibodies validated in cynomolgus models.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Zhejiang Shouxiangu Pharmaceutical Co Ltd is a Chinese pharmaceutical company.

Nika Pharmaceuticals Inc is a company involved in development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. It has acquired the exclusive rights for production and distribution of the dietary supplements Physiolong and Carotilen, as well as the drug TNG, which has been clinically tested on AIDS patients.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Encoded Therapeutics is a South San Francisco-based clinical-stage biotech developing AAV gene therapies for genetic disorders. Its lead candidate ET-001 targets Dravet syndrome via SCN1A gene augmentation, with Phase 1/2 trials ongoing. Pipeline addresses neurogenetic diseases like CNKSR2 deficiency. Founded in 2017, Encoded partners with Roche and has dosed first patients in 2023.

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Dong-A Socio Holdings Co Ltd is a pharmaceutical company. The company is engaged in the development of biomedicines and innovative drugs, and to expand businesses from pharmaceuticals to medical services and new businesses.

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.